skip to content

FDA accepts Roche's supplemental biologics license application for Tecentriq plus chemotherapy (Abraxane and carboplatin) for initial treatment of metastatic non-squamous non-small cell lung cancer

Media

Media releases
view all

stay updated

get the latest news and updates to your inbox.